Corin aims high with implants for young active patients
This article was originally published in Clinica
UK orthopaedic company Corin has filed for a listing on the London Stock Exchange and plans to raise around £22 million ($32 million). The company has developed reconstructive implants aimed at patients suffering from degenerative arthritis, with a particular emphasis on the younger patient.
You may also be interested in...
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.